
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences Inc. is positioned favorably in the immuno-oncology sector, given its focus on developing innovative solutions to combat resistance to existing cancer therapies. The upcoming Phase 3 registration trial for its personalized cancer vaccine candidate, IFx-2.0, as an adjunctive therapy to Keytruda, signifies a strategic entry into a lucrative market segment, highlighting the company's potential for substantial revenue generation. The company's advancements and pipeline developments underscore its capacity to address unmet medical needs, enhancing the long-term viability and investor interest in TuHURA’s stock.
Bears say
TuHURA Biosciences reported a net loss of $0.15 per share for the first quarter of 2025, which aligns closely with previous estimates but highlights ongoing financial challenges. The company faces significant risks, including possible negative clinical results for its personalized cancer vaccine candidate IFx-2.0, delays in advancing its pipeline candidates, and challenges in obtaining timely regulatory approvals. Additionally, competitive threats from other checkpoint inhibitors and the potential for long-term dilution raise concerns about the company's future profitability and market position.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares